白蛋白结合型紫杉醇联合吉西他滨治疗局部进展期胰腺癌的疗效观察

Clinical efficacy of Nab-paclitaxel with gemcitabine for locally advanced pancreatic cancer

目的评估白蛋白结合型紫杉醇联合吉西他滨治疗局部进展期胰腺癌的有效性及安全性。方法20例经病理确诊不能手术的局部进展期胰腺癌患者,给予白蛋白结合型紫杉醇+吉西他滨方案化疗:白蛋白结合型紫杉醇125 mg/m^2,吉西他滨1 000 mg/m^2,d1、d8给药,21 d重复1次。结果所有患者均进行疗效评价,其中完全缓解(CR)2例,部分缓解(PR)6例,疾病稳定(SD)9例,疾病进展(PD)3例。客观有效率(ORR):40%,疾病控制率(DCR):85%。中位无进展生存期(mPFS)和中位生存期(mOS)分别为5.5个月和10.3个月,1年生存率为40%。所有患者均未发生因不能耐受不良反应而停止治疗及治疗相关性死亡。其中主要的不良反应为:骨髓抑制、脱发、恶心呕吐、乏力、周围神经毒性。结论白蛋白结合型紫杉醇联合吉西他滨治疗局部进展期胰腺癌具有良好的有效性及安全性。

Objective To investigate the feasibility and efficacy of Nab-paclitaxel with gemcitabine for locally advanced pancreatic cancer. Methods Twenty patients with locally advanced pancreatic cancer confirmed by pathology were recruited in the study. All the patients were treated by Nab-paclitaxel with gemcitabine： Nab-paclitaxel 125 mg /m2 andgemabine 1 000 mg /m2 at the first and eighth day,with 21 d as a cycle. Results All the patients completed the scheduled course of chemotherapy. There were 2 cases of complete response（ CR）,6cases with partial response（ PR）and 9 cases of stable disease（ SD）. The objective response rate（ ORR） and the disease control rate（ DCR） were 40%and 85%, and the median progression-free survival（ mPFS） and median overall survival（ mOS） were 5. 5 and 10. 3months. There was no treatment-related death, and the main toxicities included hematological toxicity, alopecia,gastrointestinal reactions,f atigure and sensory neuropathy. Conclusion Nab-paclitaxel combined with gemcitabine has good efficacy and safety in the treatment of locally advanced pancreatic cancer.